Cilostazol

Summary

Cilostazol (CHEMBL799) is an approved small-molecule bronchodilator agent (ATC B01AC23) targeting PDE3A and PDE3B; indicated across 21 conditions including thrombotic disease and cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B01AC23
• Targets: 2 (PDE3A, PDE3B)
• Indications: 21 conditions
• Clinical trials: 122
• Chemistry: 369.5 Da · C20H27N5O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL799
Name	Cilostazol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2754
ChEBI	CHEBI:31401
ATC	B01AC23
Molecular formula	C20H27N5O2
Molecular weight	369.5
InChIKey	RRGUKTPIGVIEKM-UHFFFAOYSA-N

SMILES: C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4

IUPAC name: 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one

ChEBI definition: A lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substituted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group.

Pharmacological roles (ChEBI): bronchodilator agent, vasodilator agent, fibrin modulating drug, platelet aggregation inhibitor, neuroprotective agent, anticoagulant, EC 3.1.4.17 (3’,5’-cyclic-nucleotide phosphodiesterase) inhibitor.

Also known as: Cilostazol, NSC-758936, OPC-13013, OPC-21, Pletal, SID11110906, SID11113335, SID26719653, SID26746958, SID50103999, SID85230957, SID855683

Patent coverage: 4,960 distinct patent families (20,017 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 19,958 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PDE3A	phosphodiesterase 3A	Inhibition	6.7	0.1%	Q14432
PDE3B	phosphodiesterase 3B	Inhibition	6.42	0.2%	Q13370

Broader ChEMBL bioactivity targets: 25 (assay-derived). Sample: Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, RecQ-like DNA helicase BLM, Thrombopoietin, Endonuclease 4, Peripheral myelin protein 22, ATP-binding cassette sub-family C member 4, Thyrotropin receptor, Equilibrative nucleoside transporter 1, Menin/Histone-lysine N-methyltransferase MLL, Phosphodiesterase 3, Voltage-gated L-type calcium channel, Kappa-type opioid receptor, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3B, Cytochrome P450 1A2, Cytochrome P450 2C9.

Bioactivity

ChEMBL activities: 19 potent at pChembl ≥ 5 of 46 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDE3A	8.41	IC50	3.89	nM	CHEMBL_ACT_22876929
PDE3A	7.57	IC50	27	nM	CHEMBL_ACT_26105934
PDE3B	7.3	IC50	50	nM	CHEMBL_ACT_26105935
BLM	7	Potency	100	nM	CHEMBL_ACT_4749863
BLM	7	Potency	100	nM	CHEMBL_ACT_4929947
PDE3B	6.72	IC50	190	nM	CHEMBL_ACT_830058
PDE3B	6.7	IC50	200	nM	CHEMBL_ACT_25084343
PDE3B	6.55	IC50	280	nM	CHEMBL_ACT_1883871
PDE3A	6.37	AC50	423.9	nM	CHEMBL_ACT_25190398
PDE3B	6.08	IC50	840	nM	CHEMBL_ACT_2414895
SMN1	6.05	Potency	891.3	nM	CHEMBL_ACT_3867335
OPRK1	5.51	AC50	3056	nM	CHEMBL_ACT_25129167
P51450	5.5	Potency	3162	nM	CHEMBL_ACT_4766813
P51450	5.45	Potency	3548	nM	CHEMBL_ACT_4096435
MAPK1	5.45	Potency	3548	nM	CHEMBL_ACT_4721488
ALDH1A1	5.1	Potency	7943	nM	CHEMBL_ACT_4151120
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5010135
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5078506
CYP2C9	5	IC50	10000	nM	CHEMBL_ACT_7692884

Target pathways

Aggregated over 2 target gene(s): PDE3A, PDE3B.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
G alpha (s) signalling events	2	PDE3A, PDE3B
PDE3B signalling	1	PDE3B

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	2
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway	2
negative regulation of cAMP/PKA signal transduction	2
signal transduction	2
oocyte maturation	1
lipid metabolic process	1
response to xenobiotic stimulus	1
regulation of meiotic nuclear division	1
negative regulation of apoptotic process	1
negative regulation of vascular permeability	1
positive regulation of vascular permeability	1
positive regulation of oocyte development	1
regulation of ribonuclease activity	1
cellular response to cGMP	1
cellular response to transforming growth factor beta stimulus	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419

16 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
peripheral arterial disease	3	MONDO:0005386	EFO:0004265
cerebrovascular disorder	3	MONDO:0011057	EFO:0003763
cerebral infarction	3	MONDO:0002679	MONDO:0002679
coronary artery disorder	3	MONDO:0005010	EFO:0001645
peripheral vascular disease	3	MONDO:0005294	EFO:0003875
atherosclerosis	3	MONDO:0005311	EFO:0003914
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
intermittent vascular claudication	2	MONDO:0005295	EFO:0003876
stroke disorder	2	MONDO:0005098	EFO:0000712
heart failure	2	MONDO:0005252	EFO:0003144
injury	2	MONDO:0021178	EFO:0000546
urticaria	2	MONDO:0005492	EFO:0005531
fatty liver disease	1	MONDO:0004790	HP:0001397
cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1	1	MONDO:0000914	Orphanet:136
osteoarthritis	1	MONDO:0005178	MONDO:0005178

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 122.

Phase distribution

Phase	Trials
PHASE4	53
PHASE3	24
Not specified	16
PHASE2	9
PHASE1	9
PHASE1/PHASE2	6
PHASE2/PHASE3	3
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06402747	PHASE4	RECRUITING	Clopidogrel Versus Cilostazol on Vessels
NCT06757764	PHASE4	RECRUITING	The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
NCT07180472	PHASE4	NOT_YET_RECRUITING	Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol
NCT00048763	PHASE4	COMPLETED	Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
NCT00048776	PHASE4	COMPLETED	Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon
NCT00130039	PHASE4	COMPLETED	Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
NCT00234065	PHASE4	COMPLETED	Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
NCT00272454	PHASE4	COMPLETED	Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
NCT00272831	PHASE4	COMPLETED	The Use of Cilostazol in Patients With Diabetic Nephropathy
NCT00404716	PHASE4	COMPLETED	Triple Versus Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation
NCT00431249	PHASE4	COMPLETED	Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease
NCT00446641	PHASE4	COMPLETED	Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
NCT00549978	PHASE4	COMPLETED	Safety and Pharmacokinetics of Probucol and Cilostazol
NCT00573950	PHASE4	UNKNOWN	Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness
NCT00589927	PHASE4	COMPLETED	Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent
NCT00741286	PHASE4	COMPLETED	Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
NCT00776828	PHASE4	COMPLETED	The Efficacy of CILostazol ON Ischemic Complications After DES Implantation
NCT00822172	PHASE4	COMPLETED	Evaluation of Cilostazol in Combination With L-Carnitine
NCT00823849	PHASE4	COMPLETED	Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
NCT00823875	PHASE4	COMPLETED	Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker—atherosclerosis Cerebral Infarction Patient as Study Subject
NCT00847860	PHASE4	COMPLETED	Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions
NCT00886574	PHASE4	UNKNOWN	Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events
NCT00912756	PHASE4	UNKNOWN	Sufficient Treatment of Peripheral Intervention by Cilostazol
NCT00915733	PHASE4	COMPLETED	Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
NCT00938522	PHASE4	UNKNOWN	Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention
NCT01013532	PHASE4	UNKNOWN	PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
NCT01076478	PHASE4	COMPLETED	Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines
NCT01094457	PHASE4	COMPLETED	Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation
NCT01188824	PHASE4	COMPLETED	The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)
NCT01192724	PHASE4	COMPLETED	Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation
NCT01252056	PHASE4	COMPLETED	A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
NCT01291641	PHASE4	COMPLETED	Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease
NCT01328470	PHASE4	COMPLETED	Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease
NCT01346865	PHASE4	TERMINATED	Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
NCT01409564	PHASE4	COMPLETED	Cilostazol Augmentation Study in Dementia
NCT01932203	PHASE4	UNKNOWN	Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease
NCT01952756	PHASE4	COMPLETED	Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)
NCT01955200	PHASE4	COMPLETED	OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
NCT01995370	PHASE4	COMPLETED	Cilostazol Stroke Prevention Study for Antiplatelet Combination
NCT02098460	PHASE4	COMPLETED	To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject
NCT02174939	PHASE4	UNKNOWN	Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease
NCT02194686	PHASE4	COMPLETED	Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease
NCT02374957	PHASE4	TERMINATED	Cilostazol After Lower Extremity Arterial Revascularization Trial
NCT02483169	PHASE4	UNKNOWN	PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study
NCT02829151	PHASE4	UNKNOWN	Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)
NCT02933788	PHASE4	UNKNOWN	Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients
NCT02983214	PHASE4	COMPLETED	Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
NCT03116269	PHASE4	COMPLETED	The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients
NCT03248401	PHASE4	COMPLETED	Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
NCT03581409	PHASE4	COMPLETED	Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm
NCT04148105	PHASE4	TERMINATED	Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)
NCT04407312	PHASE4	UNKNOWN	Cilostazol and Endothelial Progenitor Cell
NCT06522113	PHASE4	COMPLETED	Cilostazol and Aspirin in Stroke and TIA
NCT06196047	PHASE3	RECRUITING	Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA
NCT06202755	PHASE3	RECRUITING	Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
NCT06530537	PHASE3	RECRUITING	Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds
NCT06561867	PHASE3	RECRUITING	Ticagrelor Versus Cilostazol in Ischemic Stroke
NCT06591299	PHASE3	RECRUITING	Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA
NCT06591351	PHASE3	RECRUITING	Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA
NCT06591377	PHASE3	RECRUITING	Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA
NCT06591390	PHASE3	RECRUITING	Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA
NCT06919835	PHASE3	NOT_YET_RECRUITING	CiLostAzol for pReventIon of Recurrent sTroke in Africa
NCT06989697	PHASE3	RECRUITING	Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
NCT07174414	PHASE3	NOT_YET_RECRUITING	Cilostazol for Prevention of Recurrent Stroke Trial
NCT00132743	PHASE3	UNKNOWN	Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)
NCT00202020	PHASE3	COMPLETED	Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke
NCT00333164	PHASE3	COMPLETED	Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis
NCT00766545	PHASE3	COMPLETED	Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.
NCT00891670	PHASE3	UNKNOWN	Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism
NCT02087007	PHASE3	COMPLETED	A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina
NCT02094469	PHASE3	COMPLETED	Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina
NCT02266030	PHASE3	COMPLETED	Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM
NCT02770274	PHASE3	UNKNOWN	Cilostazol Following Peripheral Endovascular Procedures
NCT03451591	PHASE2/PHASE3	COMPLETED	LACunar Intervention (LACI-2) Trial-2
NCT05594680	PHASE3	UNKNOWN	Cilostazol and Methotrexate in Rheumatoid Arthritis
NCT05671497	PHASE2/PHASE3	COMPLETED	The Effect of Cilostazol on Rheumatoid Arthritis Patients
NCT06117436	PHASE2/PHASE3	COMPLETED	Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients
NCT06242132	PHASE3	COMPLETED	Clopidogrel Versus Cilostazol in Ischemic Stroke
NCT06242145	PHASE3	COMPLETED	Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke
NCT06886620	PHASE3	TERMINATED	Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication
NCT03109288	PHASE1/PHASE2	RECRUITING	Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
NCT04753970	PHASE1/PHASE2	RECRUITING	Retina is a Marker for Cerebrovascular Heath
NCT06492070	PHASE2	RECRUITING	Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
NCT06612593	PHASE2	NOT_YET_RECRUITING	Cilostazol in Parkinson’s Disease
NCT07238985	PHASE1/PHASE2	RECRUITING	Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
NCT00443287	PHASE2	COMPLETED	Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
NCT01142284	PHASE2	COMPLETED	Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety
NCT01915069	PHASE2	COMPLETED	Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary
NCT02481323	PHASE2	COMPLETED	Lacunar Intervention Trial 1 (LACI-1)
NCT02491268	PHASE2	COMPLETED	A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)
NCT03855332	PHASE2	COMPLETED	Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial
NCT04761848	PHASE1/PHASE2	WITHDRAWN	Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
NCT04789837	PHASE1/PHASE2	WITHDRAWN	The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis
NCT05298696	PHASE1/PHASE2	COMPLETED	Efficacy of Cilostazol in Prevention of Peripheral Neuropathy
NCT06138834	PHASE2	UNKNOWN	EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
NCT00648388	PHASE1	COMPLETED	Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg
NCT00773630	PHASE1	COMPLETED	A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions
NCT01383395	PHASE1	COMPLETED	Effect of Cilostazol on the Pharmacokinetics of Simvastatin
NCT01870466	PHASE1	COMPLETED	Pharmacodynamic Drug Interaction Between Cilostazol and Statins
NCT02431013	PHASE1	UNKNOWN	Cilostazol-Simvastatin Drug Interaction Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 11 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

200 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
ANAGRELIDE	ChEMBL + PubChem	Phase 4 (approved)	PDE3A, PDE3B
LOSARTAN	ChEMBL + PubChem	Phase 4 (approved)	PDE3A, PDE3B
SILDENAFIL	ChEMBL + PubChem	Phase 4 (approved)	PDE3A, PDE3B
VARDENAFIL	ChEMBL + PubChem	Phase 4 (approved)	PDE3A, PDE3B
CRISABOROLE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
DIPYRIDAMOLE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
ENOXIMONE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
IBUDILAST	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
INAMRINONE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
MILRINONE	ChEMBL	Phase 4 (approved)	PDE3A, PDE3B
LEVOSIMENDAN	ChEMBL	Phase 3	PDE3A, PDE3B
PAPAVERINE	ChEMBL	Phase 3	PDE3A, PDE3B
ADIBENDAN	ChEMBL	Phase 2	PDE3A, PDE3B
BEMARINONE	ChEMBL	Phase 2	PDE3A, PDE3B
BEMORADAN	ChEMBL	Phase 2	PDE3A, PDE3B
CC-115	ChEMBL	Phase 2	PDE3A, PDE3B
CILOSTAMIDE	ChEMBL	Phase 2	PDE3A, PDE3B
ETAZOLATE	ChEMBL	Phase 2	PDE3A, PDE3B
IMAZODAN	ChEMBL	Phase 2	PDE3A, PDE3B
INDOLIDAN	ChEMBL	Phase 2	PDE3A, PDE3B
ISOMAZOLE	ChEMBL	Phase 2	PDE3A, PDE3B
LIXAZINONE	ChEMBL	Phase 2	PDE3A, PDE3B
MEDORINONE	ChEMBL	Phase 2	PDE3A, PDE3B
MERIBENDAN	ChEMBL	Phase 2	PDE3A, PDE3B
ORISMILAST	ChEMBL	Phase 2	PDE3A, PDE3B
OXAGRELATE	ChEMBL	Phase 2	PDE3A, PDE3B
PIMOBENDAN	ChEMBL	Phase 2	PDE3A, PDE3B
PIROXIMONE	ChEMBL	Phase 2	PDE3A, PDE3B
QUAZINONE	ChEMBL	Phase 2	PDE3A, PDE3B
SIMENDAN	ChEMBL	Phase 2	PDE3A, PDE3B
SULMAZOLE	ChEMBL	Phase 2	PDE3A, PDE3B
VESNARINONE	ChEMBL	Phase 2	PDE3A, PDE3B
ZARDAVERINE	ChEMBL	Phase 2	PDE3A, PDE3B
Tadalafil	PubChem	Approved	PDE3A, PDE3B
CLOFARABINE	ChEMBL + PubChem	Phase 4 (approved)	PDE3A
IDELALISIB	ChEMBL + PubChem	Phase 4 (approved)	PDE3A
TAFAMIDIS	ChEMBL + PubChem	Phase 4 (approved)	PDE3A
TAVABOROLE	ChEMBL + PubChem	Phase 4 (approved)	PDE3A
ACARBOSE	ChEMBL	Phase 4 (approved)	PDE3A
ADENOSINE	ChEMBL	Phase 4 (approved)	PDE3A
ALECTINIB	ChEMBL	Phase 4 (approved)	PDE3A
ALENDRONIC ACID	ChEMBL	Phase 4 (approved)	PDE3A
AMINOGLUTETHIMIDE	ChEMBL	Phase 4 (approved)	PDE3A
AMLEXANOX	ChEMBL	Phase 4 (approved)	PDE3A
ANTAZOLINE	ChEMBL	Phase 4 (approved)	PDE3A
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	PDE3A
BENAZEPRIL	ChEMBL	Phase 4 (approved)	PDE3A
BENZBROMARONE	ChEMBL	Phase 4 (approved)	PDE3A
BITHIONOL	ChEMBL	Phase 4 (approved)	PDE3A
CABOZANTINIB	ChEMBL	Phase 4 (approved)	PDE3A
CALCITRIOL	ChEMBL	Phase 4 (approved)	PDE3A
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	PDE3A
CANNABIDIOL	ChEMBL	Phase 4 (approved)	PDE3A
CEFOPERAZONE	ChEMBL	Phase 4 (approved)	PDE3A
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	PDE3A
CHLOROQUINE	ChEMBL	Phase 4 (approved)	PDE3A
CHOLIC ACID	ChEMBL	Phase 4 (approved)	PDE3A
CINNARIZINE	ChEMBL	Phase 4 (approved)	PDE3A
CLADRIBINE	ChEMBL	Phase 4 (approved)	PDE3A
CODEINE	ChEMBL	Phase 4 (approved)	PDE3A
DEOXYCHOLIC ACID	ChEMBL	Phase 4 (approved)	PDE3A
DEQUALINIUM	ChEMBL	Phase 4 (approved)	PDE3A
DISOPYRAMIDE	ChEMBL	Phase 4 (approved)	PDE3A
DUVELISIB	ChEMBL	Phase 4 (approved)	PDE3A
EFAVIRENZ	ChEMBL	Phase 4 (approved)	PDE3A
ENCORAFENIB	ChEMBL	Phase 4 (approved)	PDE3A
ESTRADIOL CYPIONATE	ChEMBL	Phase 4 (approved)	PDE3A
ESTRADIOL VALERATE	ChEMBL	Phase 4 (approved)	PDE3A
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	PDE3A
FEXOFENADINE	ChEMBL	Phase 4 (approved)	PDE3A
GEMCITABINE	ChEMBL	Phase 4 (approved)	PDE3A
GRISEOFULVIN	ChEMBL	Phase 4 (approved)	PDE3A
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	PDE3A
HYDROXOCOBALAMIN	ChEMBL	Phase 4 (approved)	PDE3A
HYDROXYPROGESTERONE CAPROATE	ChEMBL	Phase 4 (approved)	PDE3A
IBANDRONIC ACID	ChEMBL	Phase 4 (approved)	PDE3A
IDEBENONE	ChEMBL	Phase 4 (approved)	PDE3A
IFOSFAMIDE	ChEMBL	Phase 4 (approved)	PDE3A
ILOPERIDONE	ChEMBL	Phase 4 (approved)	PDE3A
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	PDE3A
IRBESARTAN	ChEMBL	Phase 4 (approved)	PDE3A
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	PDE3A
ISRADIPINE	ChEMBL	Phase 4 (approved)	PDE3A
LAMIVUDINE	ChEMBL	Phase 4 (approved)	PDE3A
LAMOTRIGINE	ChEMBL	Phase 4 (approved)	PDE3A
MASOPROCOL	ChEMBL	Phase 4 (approved)	PDE3A
MECLIZINE	ChEMBL	Phase 4 (approved)	PDE3A
METHICILLIN	ChEMBL	Phase 4 (approved)	PDE3A
MIZOLASTINE	ChEMBL	Phase 4 (approved)	PDE3A
MOEXIPRIL	ChEMBL	Phase 4 (approved)	PDE3A
MOFEZOLAC	ChEMBL	Phase 4 (approved)	PDE3A
MONTELUKAST	ChEMBL	Phase 4 (approved)	PDE3A
MYCOPHENOLATE MOFETIL	ChEMBL	Phase 4 (approved)	PDE3A
NEVIRAPINE	ChEMBL	Phase 4 (approved)	PDE3A
NISOLDIPINE	ChEMBL	Phase 4 (approved)	PDE3A
NITROFURAZONE	ChEMBL	Phase 4 (approved)	PDE3A
NORETHYNODREL	ChEMBL	Phase 4 (approved)	PDE3A
OLAPARIB	ChEMBL	Phase 4 (approved)	PDE3A
OLMESARTAN MEDOXOMIL	ChEMBL	Phase 4 (approved)	PDE3A
PAMIDRONIC ACID	ChEMBL	Phase 4 (approved)	PDE3A